CD4 cell count and initiation of antiretroviral therapy: Trends in seven UK centres, 1997-2003

HIV Medicine

Volumn 8, Issue 3, 2007, Pages 135-141

  Stöhr, Wolfgang ^a   Dunn, David T ^a,i   Porter, Kholoud ^a,i   Hill, Teresa ^b   Gazzard, Brian ^c,k   Walsh, John ^d,m   Gilson, Richard ^b   Easterbrook, Philippa ^e,j   Fisher, Martin ^f   Johnson, Margaret A ^g,l   Delpech, Valerie C ^h   Phillips, Andrew N ^b   Sabin, Caroline A ^b   Ainsworth, Jonathan ^o   Anderson, Jane ^a   Babiker, Abdel ⁱ   Gompels, Mark ^o   Leen, Clifford ^o   Orkin, Chloe ⁿ   Pillay, Deenan ^o   Schwenk, Achim ^o   Bansi, Loveleen ^b   Patel, Sandeep ⁱ   Sheehan, Stephen ⁱ   Duffell, Stephen ^j   Bazuaye, Eghosa ^j   Macfarlane, Emma ^j   Perry, Nicky ^f   Pullin, Anthony ^f   Churchill, Duncan ^f   Harris, Wendy ^f   Bulbeck, Steve ^k   Mandalia, Sundhiya ^k   Clarke, Jemima ^k   Dodds, Julie ^b   Rider, Andy ^b   Williams, Ian ^b   Sinka, Katy ^h   Youle, Mike ^l   Lampe, Fiona ^l   Gumley, Helen ^l   Chaloner, Clinton ^l   Puradiredja, Dewi Ismajani ^l   Weber, Jonathan ^m   Kemble, Christian ^m   Thomas, Rachel ⁿ   Jones, Kevin ^a,n   Hand, James ⁿ   Gann, Selina ^a   Wilson, Alan ^o   more..

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^d IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f UK   (United Kingdom)

^g ROYAL FREE HOSPITAL   (United Kingdom)

^h PUBLIC HEALTH ENGLAND   (United Kingdom)

ⁱ MEDICAL RESEARCH COUNCIL   (United Kingdom)

^j KING S COLLEGE HOSPITAL   (United Kingdom)

^k CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^l ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^m ST MARY S HOSPITAL   (United Kingdom)

ⁿ BARTS HEALTH NHS TRUST   (United Kingdom)

^o Royal Free and University College Medical School ^*

more..

Author keywords

1997; 2003; Antiretroviral agents; Guideline adherence; HIV infections

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL PRACTICE; DRUG ABUSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROBABILITY; TREND STUDY; UNITED KINGDOM; VIRUS LOAD;

ADULT; AGE FACTORS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; GREAT BRITAIN; GUIDELINE ADHERENCE; HIV; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; SEX FACTORS; VIRAL LOAD;

EID: 34250314067     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2007.00443.x     Document Type: Article

References (28)

1. Gazzard B. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2005; 6 (Suppl. 2): 1-61.
2. Gazzard B, Moyle G. Revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. BHIVA Guidelines Writing Committee. Lancet 1998; 352: 314-316.
3. BHIVA Writing Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2000; 1: 76-101.
4. BHIVA Writing Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2001; 2: 276-313.
5. Curtis H, Sabin CA, Johnson MA. Findings from the first national clinical audit of treatment for people with HIV. HIV Med 2003; 4: 11-17.
6. Brook MG, Curtis H, Johnson MA. Findings from the British HIV Association's national clinical audit of first-line antiretroviral therapy and survey of treatment practice and maternity care. HIV Med 2004; 5: 415-420.
7. CHIC Steering Committee. The creation of a large UK-based multicentre cohort of HIV-infected individuals: The UK Collaborative HIV Cohort (UK CHIC) Study. HIV Med 2004; 5: 115-124.
8. Bassetti S, Battegay M, Furrer H et al. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 1999; 21: 114-119.
9. CASCADE Collaboration. Changes in the uptake of antiretroviral therapy and survival in people with known duration of HIV infection in Europe: results from CASCADE. HIV Med 2000; 1: 224-231.
10. Mocroft A, Madge S, Johnson AM et al. A comparison of exposure groups in the EuroSIDA study: Starting highly active antiretroviral therapy (HAART), response to HAART, and survival. J Acquir Immune Defic Syndr 1999; 22: 369-378.
11. Mocroft A, Gill MJ, Davidson W, Phillips AN. Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care? J Acquir Immune Defic Syndr 2000; 24: 475-482.
12. Pezzotti P, d'Arminio Monforte A, Bugarini R et al. Antiretroviral therapy in HIV-infected individuals in clinical practice: Are the criteria for initiating and choosing the type of drug regimen based only on immunologic and virologic values? Eur J Epidemiol 2000; 16: 919-926.
13. McNaghten AD, Hanson DL, Dworkin MS, Jones JL. Differences in prescription of antiretroviral therapy in a large cohort of HIV-infected patients. J Acquir Immune Defic Syndr 2003; 32: 499-505.
14. Cunningham WE, Markson LE, Andersen RM et al. Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the United States. HCSUS Consortium. HIV Cost and Services Utilization. J Acquir Immune Defic Syndr 2000; 25: 115-123.
15. Gebo KA, Fleishman JA, Conviser R et al. Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients. J Acquir Immune Defic Syndr 2005; 38: 96-103.
16. Phillips AN, Lee CA, Elford J, Janossy G, Kernoff PB. The cumulative risk of AIDS as the CD4 lymphocyte count declines. J Acquir Immune Defic Syndr 1992; 5: 148-152.
17. Chadborn TR, Baster K, Delpech VC et al. No time to wait: How many HIV-infected homosexual men are diagnosed late and consequently die? (England and Wales, 1993-2002). AIDS 2005; 19: 513-520.
18. Sullivan AK, Curtis H, Sabin CA, Johnson MA. Newly diagnosed HIV infections: Review in UK and Ireland. Br Med J 2005; 330: 1301-1302.
19. Bogart LM, Kelly JA, Catz SL, Sosman JM. Impact of medical and nonmedical factors on physician decision making for HIV/AIDS antiretroviral treatment. J Acquir Immune Defic Syndr 2000; 23: 396-404.
20. Phillips A. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era. AIDS 2004; 18: 51-58.
21. D'Arminio Monforte A, Cozzi-Lepri A, Phillips A et al. Interruption of highly active antiretroviral therapy in HIV clinical practice: Results from the Italian Cohort of Antiretroviral-Naive Patients. J Acquir Immune Defic Syndr 2005; 38: 407-416.
22. El-Sadr W, Neaton J for the SMART Study Investigators. Episodic CD4-guided use of ART is inferior to continuous therapy: Results of the SMART Study. 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, February 2006 [Abstract 106LB].
23. Danel C, Moh R, Sorho S et al. The CD4-guided strategy arm stopped in a randomized structured treatment interruption trial in West-African adults: ANRS 1269 Trivacan Trial. 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, February 2006 [Abstract 105LB].
24. Smith DE, Walker BD, Cooper DA, Rosenberg ES, Kaldor JM. Is antiretroviral treatment of primary HIV infection clinically justified on the basis of current evidence? AIDS 2004; 18: 709-718.
25. Porter K for the CASCADE Collaboration. Determinants of CD4 normalisation for individuals presenting with CD4<350 cells/ml at seroconversion. XV International AIDS Conference. Bangkok, Thailand, July 2004 [Abstract MoPeC3370].
26. Junghans C, Low N, Chan P, Witschi A, Vernazza P, Egger M. Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort Study. AIDS 1999; 13: 2547-2554.
27. Sabin CA, Smith CJ, Gumley H et al. Late presenters in the era of highly active antiretroviral therapy: Uptake of and responses to antiretroviral therapy. AIDS 2004; 18: 2145-2151.
28. Shapiro MF, Morton SC, McCaffrey DF et al. Variations in the care of HIV-infected adults in the United States: Results from the HIV Cost and Services Utilization Study. J Am Med Assoc 1999; 281: 2305-2315.